Philip Morris International Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PM research report →
Range $201 – $225
Price Chart
About the company
Philip Morris International Inc. functions as a prominent tobacco enterprise, actively working toward a smoke-free future. The company is strategically diversifying its long-term product range to incorporate items beyond traditional tobacco and nicotine.
- CEO
- Jacek Olczak
- IPO
- 2008
- Employees
- 84,900
- HQ
- Stamford, CT, US
Get TickerSpark's AI analysis on PM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $286.93B
- P/E
- 28.38
- Fwd P/E
- 22.07
- PEG
- 1.19
- P/S
- 7.02
- P/B
- -38.27
- EV/EBITDA
- 18.33
- Div Yield
- 3.09%
- Gross Margin
- 67.74%
- Op Margin
- 38.62%
- Net Margin
- 24.82%
- ROE
- -119.68%
- ROIC
- 27.48%
Latest fiscal year · YoY change
- Revenue
- $40.65B+7.3%
- Gross Profit
- $27.28B+11.1%
- Op Income
- $14.89B
- Net Income
- $11.35B+61.3%
- EPS
- $7.27+60.5%
- OCF Growth
- +0.1%
- FCF Growth
- -1.0%
- 52W High
- $214.35
- 52W Low
- $146.35
- 50D MA
- $196.83
- 200D MA
- $183.50
- Beta
- 0.36
- RSI (14)
- 33
- Avg Volume
- 4.67M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
PMI posted strong Q3 results with broad-based smoke-free growth, record quarterly EPS and margin expansion, while raising full-year guidance but flagging heavier U.S. investment and inflation/geopolitical costs in Q4.· October 21, 2026
- Q3 organic net revenue grew 7.1% to $11.4 billion, adjusted operating income rose 10.5% organically, and adjusted diluted EPS increased to a record $2.36.
- Smoke-free momentum remained strong: total smoke-free shipments rose 2.7%, IQOS adjusted IMS grew 7.1%, VEEV shipments jumped 62%, and ZYN growth accelerated.
- Combustibles were resilient, with cigarette shipments flat versus an industry decline and international pricing of 8.9% helping drive share gains and profit growth.
- Management kept full-year organic revenue guidance at 5%-7% and OI growth at 7%-9%, but said delivery is more likely in the midpoint or lower half because of geopolitics and elevated U.S. spending.
- The company raised its dividend again and expects about $13.5 billion of operating cash flow for the year.
Reported Q3 organic net revenue grew 7.1% to $11.4 billion, or 5.5% in dollar terms. Adjusted operating income increased 10.5% organically and 9.6% in dollar terms, with adjusted OI margin reaching close to 45%. Adjusted diluted EPS rose 5.4% to $2.36, a quarterly record, with 6% growth excluding currency as stated by management. Year to date, organic net revenue grew 5.9% to nearly $33 billion, adjusted OI rose 7.7% organically to more than $14 billion, and adjusted diluted EPS was $6.52, up 8.4% excluding currency. For the full year, PMI reiterated guidance for organic net revenue growth of 5%-7%, organic OI growth of 7%-9%, and currency-neutral adjusted diluted EPS growth of 7.5%-9.5%, which implies $8.29-$8.44 including the estimated $0.18 currency tailwind. Management also expects HTU shipment growth of 39.5 billion-40.5 billion units in Q4, full-year total shipment growth, and about $13.5 billion of operating cash flow.
The lead strategic message was that PMI’s smoke-free transition is scaling across IQOS, ZYN and VEEV, while combustibles continue to provide resilient cash generation and pricing. Management emphasized that the business is on track for a sixth consecutive year of total shipment growth and said international smoke-free growth remains broadening geographically, with multiple markets now delivering double-digit progress. Tone was confident and upbeat, but with clear acknowledgment that Q4 will be unusually investment-heavy in the U.S. and that geopolitical inflation remains a drag.
Massimo Andolina said Q3 reflected strong top-line leverage, with organic gross profit up more than 8% and adjusted OI margin near 45%, supported by about 80 basis points of gross margin expansion both in Q3 and year to date. He also highlighted that cumulative gross cost savings since 2024 have topped $2 billion, ahead of the three-year target. On capital allocation, he pointed to a raised annual dividend to $6.40 per share, the 19th consecutive increase, and said PMI remains highly cash generative with expected operating cash flow of roughly $13.5 billion, giving flexibility to invest, deleverage and return cash. He repeatedly tied the softer outlook for the full year to roughly half a point of EPS pressure from inflationary/geopolitical costs plus another half point from Ukraine disruptions, alongside elevated U.S. commercial spending and Colorado ramp-up costs.
Analysts focused on why full-year OI/EPS guidance was not raised more after an above-plan quarter, and management said the main reasons were worsening geopolitical cost pressures, Ukraine-related supply-chain disruptions, and exceptional U.S. investment tied to ZYN portfolio changes and brand building. On ZYN, questions centered on whether the new flavors and higher-nicotine variants are working and whether moving flagship cans from 15 to 20 pouches could alter consumer behavior; management said early consumer response was overwhelmingly positive and described the 20-pouch change as a deliberate price/value repositioning, not a sign of weakness. Analysts also pressed on the gap between U.S. shipment growth and scanner data, and management pointed to comparisons with prior-year promotions plus distribution build for new variants. On IQOS, management said shipments should slightly trail IMS because of Japan phasing and pantry loading, while inventories should come down but remain healthy.
The bull case from this call is that PMI’s smoke-free portfolio continues to scale in multiple geographies, with IQOS, ZYN and VEEV all showing strong momentum and category share gains. Management sounded confident that the current U.S. investment cycle is setting up longer-term growth, while international smoke-free and combustible businesses are still delivering strong margins and cash generation.
The main risks highlighted were higher-than-expected inflationary and geopolitical costs, especially in Q4, plus ongoing disruptions in Ukraine and a volatile energy/shipping backdrop. The U.S. ZYN reset is expensive in the near term, with management expecting Q4 adjusted OCI around break-even or slightly negative, and full-year results likely landing only in the midpoint or lower half of guidance despite a strong third quarter.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 1.56B
- Float Shares
- 1.56B
of shares held by institutions
3,019 13F filers
Congressional trading
Senate and House stock disclosures for PM, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jun 2, 26 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Feb 5, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Dec 18, 25 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Oct 23, 24 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Nov 13, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 30, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 30, 25 | Filing → |
| Sheri BiggsHouse · SC03 | Sell | Mar 19, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 29, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 5, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 26, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 145.26M | ▲ 1.79M |
| Capital World Investors | 130.42M | ▼ 2.73M |
| Blackrock, Inc. | 108.64M | ▲ 595.78K |
| Vanguard Capital Management LLC | 102.02M | ▲ 237.54K |
| Capital Research Global Investors | 85.60M | ▲ 1.35M |
| Capital International Investors | 67.13M | ▼ 5.13M |
| State Street Corp | 56.30M | ▲ 728.17K |
| Jpmorgan Chase & Co | 55.99M | ▲ 7.80M |
| Fmr LLC | 55.54M | ▲ 9.02M |
| Geode Capital Management, LLC | 39.61M | ▲ 571.38K |
| Vanguard Portfolio Management LLC | 30.40M | ▲ 122.36K |
| Morgan Stanley | 28.30M | ▲ 2.81M |
Held by 1,583 ETFs
Biggest fund positions in PM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 1, 26 | Andolina Massimo | other | 0 |
| May 6, 26 | Combes Michel | other | 1,119 |
| May 6, 26 | Geissler Werner | other | 1,119 |
| May 6, 26 | Morparia Kalpana | other | 1,119 |
| May 6, 26 | Harker Victoria D | other | 1,119 |
| May 6, 26 | Polet Robert | other | 1,119 |
| May 6, 26 | Bough Bonin | other | 1,119 |
| May 6, 26 | Hook Lisa | other | 1,119 |
| May 6, 26 | Calantzopoulos Andre | other | 1,119 |
| May 6, 26 | Yanai Shlomo | other | 1,119 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PM coverage
Recent articles, reports, and earnings notes.

Philip Morris International (PM): Smoke-Free Growth vs. Valuation
Philip Morris International is executing a profitable shift toward smoke-free products, with IQOS, ZYN, and VEEV driving growth. The stock looks high quality, but leverage and a rich valuation keep the rating at Hold.

Philip Morris International Inc. (PM) rises on ZYN boost
Philip Morris International Inc. (PM) rises after a strong Q2 earnings beat and fresh optimism around ZYN, IQOS, and VEEV. The stock moved above its listed 52-week high as investors reprice PMI’s smoke-free growth story, though trading volume has not confirmed a broad breakout.

Philip Morris International (PM): Smoke-Free Growth Drives the Thesis
Philip Morris International is evolving from a cigarette cash cow into a smoke-free growth story, with reduced-risk products now approaching half of revenue. Strong execution in IQOS and other nicotine alternatives supports the Buy case, though leverage and valuation keep upside measured.
Want a deeper read on PM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Philip Morris: My Thesis Has Played Out, Smoke-Free Transition Looks Priced In (Rating Downgrade)
seekingalpha.com · Nov 20
Philip Morris vs. British American Tobacco: Which Tobacco Dividend Is Better for Retirees?
247wallst.com · Nov 18
Philip Morris: Still A Buy To Me After The ZYN Price Cut
seekingalpha.com · Nov 18
Philip Morris International Inc. $PM Stock Bought by Bogart Wealth LLC
defenseworld.net · Nov 18
AlTi Global Inc. Sells 35,879 Shares of Philip Morris International Inc. $PM
defenseworld.net · Nov 16
The Roth IRA Mistake That Turns $5,275 a Month in Tax-Free Dividends Into a Tax Bill
247wallst.com · Nov 13
Philip Morris International Inc. $PM Stock Sold by CenterBook Partners LP
defenseworld.net · Nov 13
Philip Morris International Inc. $PM Shares Acquired by Allspring Global Investments Holdings LLC
defenseworld.net · Nov 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.